Personalised Medicine Strategies – Providing More Clinical Benefit
3 years ago
By Ben Parkes
Current personalised medicine strategies provide limited clinical benefit – how do we do better?
Luckily Dr Allan Jordan, the Director of Oncology Drug Discovery at leading CRO Sygnature Discovery, was on hand to explain how. Here’s another chance to watch his fascinating keynote presentation, packed full of fresh insights, data and takeaways.
The next chance to here the latest clinical insights, including more on personalised medicine strategies, will be at our clinical Online Strategy Meetings in November. For more information check out the links below:
Clinical Operations Strategy Meeting – November 16
Clinical Trial Supply Chain Strategy Meeting – November 18
Pharmacovigilance Strategy Meeting – November 19
Raising Representation in Clinical Trials: An Interview with Liz Beatty, Inato
The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...
2 years agoRaising Representation in Clinical Trials: An Interview with Liz Beatty, Inato
The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...
2 years ago
How Predictive Modelling Can Change Personalised Medicine
Personalised medicine - treatments which focus on the individual patient or sub-population, not simply prescribing a generic treatment to a large swathe of patients - has been a key target in healthcare for a long time now. New technologies, including...
2 years agoHow Predictive Modelling Can Change Personalised Medicine
Personalised medicine - treatments which focus on the individual patient or sub-population, not simply prescribing a generic treatment to a large swathe of patients - has been a key target in healthcare for a long time now. New technologies, including...
2 years ago
The Potential of Therapeutic Psychedelics Drugs: An Interview with Professor Albert Garcia-Romeu
Mental health conditions like addiction and diseases like Alzheimer’s represent a great unmet clinical need. Psychedelic research at preclinical stages have shown potential for positive neurological changes in the brain for models of depression, addiction and Alzheimer's. In a recent...
2 years agoThe Potential of Therapeutic Psychedelics Drugs: An Interview with Professor Albert Garcia-Romeu
Mental health conditions like addiction and diseases like Alzheimer’s represent a great unmet clinical need. Psychedelic research at preclinical stages have shown potential for positive neurological changes in the brain for models of depression, addiction and Alzheimer's. In a recent...
2 years ago